PPARs are members of the superfamily of nuclear hormone receptors that function as ligand-dependent transcription factors (reviewed in (1)). Upon ligand activation they regulate the expression of genes containing specific response elements, called PPREs (2, 3). Three receptor subtypes of peroxisome proliferator activated identified (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . These receptors heterodimerize with the retinoid X receptor (RXR) and alter the transcription of target genes after binding to PPREs, which consist of a hexameric nucleotide direct repeat of the recognition motif (TGACCT) spaced by 1 nucleotide (DR-1). After activation, PPARs control the expression of genes implicated in intra-and extra-cellular lipid metabolism, such as the genes encoding enzymes involved in the peroxi- adipocyte differentiation.
Since most of the target genes of PPAR are involved in the control of lipid and energy metabolism and since PPAR itself is activated by lipids, such as fatty acids and prostaglandins, it is evident that the family of PPARs plays a pivotal role in the translation of nutritional signals into changes in gene expression.
Taking its pivotal role in controlling lipid metabolism into account it is expected that PPAR has also a regulatory role in the pathogenesis of hyperlipidemia and atherosclerosis.
Similarly, it is expected that PPAR has a major function in controlling cell proliferation and differentiation, and development as Apo C-III is a major component of plasma chylomicrons and very low density lipoproteins (VLDL) and is a minor component of high density lipoproteins (HDL). Apo C-111 is a 79 amino acid glycoprotein produced predominantly in the liver and to a lesser extent in the intestine. Although it is a very abundant apolipoprotein in human plasma its exact function in vivo is not yet fully understood.
Apo C-III has been shown to inhibit hydrolysis of triglycerides by LPL in vitro (39, 40) . It also inhibits apo E-mediated clearance of lipoproteins by liver cells (41, 42), although it does not appear to affect binding of lipoproteins to the LDL receptor-related protein (43). These observations are compatible with apo C-III playing a role in the catabolism of triglyceride-rich lipoproteins.
Further evidence for a role of apo C-III in triglyceride metabolism comes from a study in subjects deficient in apo C-III (due to a deletion of the apo A1/C3/A4 region). These patients exhibit an increased catabolic rate of VLDL and an unusually efficient conversion of VLDL to intermediate density lipoproteins and LDL (40) . In contrast, elevated apo C-III synthetic rates have been observed in hypertriglyceridemic patients (44). Furthermore, genetic studies have identified several apo C-III gene polymorphisms which may be associated with increased plasma apo C-III levels and hypertriglyceridemia (45, 46) . The strongest evidence for a role of apo C-III in lipid homeostasis comes, however, from studies in transgenic animals. In animals overexpressing apo C-III marked hypertriglyceridemia was found (47, 48) whereas in animals mutant for both apo C-III alleles hypotriglyceridemia was observed (49). The animals with a targeted disruption of the apolipoprotein C-III gene were furthermore protected from postprandial hypertriglyceridemia, a predisposing factor for the development of atherosclerotic vascular disease (49). Recently, it has become clear that apo C-III might not only play a role in the metabolism of triglyceride-rich lipoproteins but that it may also be implicated in the metabolism of the atherogenic LDL particles.
Like LpB particles, complex apo B containing particles such as LpE : B or LpC-III : B are also atherogenic.
In fact in males with angiographically documented CAD, LpC-III : B showed a significant correlation with the severity of CAD. This result corresponds with those of a population study in which three cities (Belfast, Strasbourg, Toulouse) were compared (50). LpC-III : B levels were significantly increased in the population with the highest coronary mortality rate (Belfast) (50). Also within each of the studied groups an association between LpC-III : B concentrations and CAD was found (50).
Lipoprotein lipase (LPL), a secreted enzyme with a relative molecular mass of 57,000 which functions as a homodimer, is another important factor in triglyceride metabolism.
LPL synthesis occurs in several cell types and tissues including adipocytes, monocytes, neonatal (but not adult) liver, skeletal and cardiac muscle (reviewed in (51)). After secretion LPL binds to glycosaminoglycans on the luminal surface of the capillary endothelium, where it hydrolyzes core triglycerides in triglyceride-rich lipoproteins, such as chylomicrons and VLDL (reviewed in (51)). The released free fatty acids are either oxidized to generate ATP in muscle, stored in adipose tissue, or secreted in milk by the mammary gland. LPL therefore occupies a pivotal position in both lipoprotein and energy metabolism.
Recently LPL has been shown to have several additional functions including retention of LDL and VLDL particles on the cell surface and in the subendothelial matrix. Furthermore LPL acts as a ligand for the LDL receptor-related protein (LRP) and as such is not only involved in the metabolism but also the removal of TGrich lipoproteins from the circulation.
A large body of evidence links diminished LPL activity to hypertriglyceridemia. Indeed, subjects with familial LPL deficiency, a relatively rare autosomal recessive disorder, suffer from severe fasting hypertriglyceridemia due to the accumulation of chylomicrons (52). However, more subtle abnormalities in LPL activity can also lead to elevations in triglyceride concentrations (53, 54) . Most interestingly diminished LPL activity was found in a large subset of patients with familial combined hyperlipidemia, a frequent hereditary cause of CAD (53, 54). A mechanistic explanation for the role of LPL in familial combined hyperlipidemia, a disease characterized by increased secretion of apo B-containing particles, was presented by Williams et al. (55) . These investigators showed that the net secretion rate of apo B-containing particles is reduced by enhanced re-uptake of nascent lipoproteins, a mechanism facilitated after modification of the lipoproteins by LPL (55).
Alterd Transcription of the APO C-III and LPL Genes caused by Activated PPARs
Fibrates and thiazolidinediones are known to lower serum triglyceride levels (56, 57), but the exact mechanism by which they affect triglyceride levels is currently unknown. Clinical studies suggested that part of their beneficial effects on lipoprotein metabolism is due to the induction of LPL activity (reviewed in (57)) and to their apo C-III lowering effects.
Given the pivotal role of PPAR in lipid metabolism, it was investigated whether the hypotriglyceridemic actions of fibrates and thiazolidinediones were mediated by a PPAR-induced change in transcription of these genes.
Treatment of adult rats in vivo with fibrates results in a decrease in plasma triglyceride concentrations. This is accompanied by a tissue-specific, dose-and timedependent, reversible decrease of liver apo C -III gene transcription.
In contrast, fibrates reinduce liver LPL gene expression (adult liver normally does not produce LPL) (38). Since all three fibrates (fenofibrate, clofibrate and gemfibrozil) tested lower hepatic apo C -III and This triglyceride-lowering involves changing the transcription rates of the LPL (induction in adipose tissue by thiazolidinediones) and apo C-III genes (reduction in adipose tissue by fibrates). 
Clinical Effects of Treatment with Fibrates
Due to the novelty of the thiazolidinediones only a limited amount of information is available about their lipid lowering effects in clinical practice and hence the following section mainly contains data about fibrates, for whom it is well established that they reduce plasma triglyceride concentrations.
Previous clinical reports have indicated that this hypotriglyceridemic effect of fibrates is accompanied by both a decrease in plasma concentration and synthesis rate of apo C-lll (44) and an increase in LPL activity (62, 63, 65, 68, 69) . Therefore we propose the following dual action of fibrates.
First, a lowered secretion of apo C-lll, along with unchanged apo E secretion, may lead to a decreased apo C-lll/apo E ratio of triglyceride-rich particles, which then could be more efficiently cleared from plasma. Indeed, studies on transgenic mice have shown that overexpression of apo C-lll leads to an hypertriglyceridemia due to a diminished clearance rate of triglyceride-rich lipoproteins containing increased amounts of apo C-lll and reduced apo E on the particles (48, 70) . This apo C-lll induced hypertriglyceridemia could be corrected by simultaneous overexpression of apo E, indicating that apo C-lll may be implicated in modulating the apo E-mediated lipoprotein clearance (48). Furthermore, the decrease in apo C-lll production after fibrate treatment also results in a decrease in the concentration of the atherogenic LpC-lll : B particles (71). Second, enhanced transcription of the LPL gene (in the liver)) might result in higher LPL protein and activity levels (62, 63, 65, 68, 69) . Since apo C-lll has been suggested to be an inhibitor of LPL activity, the decrease in plasma apo C-lll concentrations may hence also contribute to an improved lipolysis of triglyceride-rich lipoproteins in plasma (39). Consistent with this hypothesis, fibrate induced increases in LPL activity have been previously observed both in control (62, 68) and hyperlipidemic human subjects (63, 65, 69) . Consequently, treatment with fibrates will lead to alterations in plasma apolipoprotein composition, as well as an enhanced lipolytic activity, both favouring the clearance of triglyceride-rich lipoproteins. Therefore, the decrease in apo C-III and the increase in LPL gene expression by fibrates provides a potential mechanism by which these drugs induce a less atherogenic plasma lipoprotein profile.
Tissuue-selective
Effects of Different PPAR Activators
The tissue-selective effects of the PPAR activators/ ligands are highly intriguing and provide insight in their effects on triglyceride metabolism.
Fibrate treatment reduced apo C-lll expression and induced LPL expression strongest in liver, whereas BRL 49653 had no effect on 
Conclusions
In conclusion, the role of apolipoprotein C-lll and the enzymes LPL, in governing triglyceride metabolism , was discussed.
Both clinical as well as laboratory evidence suggested the importance of both components in determining triglyceride concentrations.
Next it was investigated whether the hypotriglyceridemic effects of fibrates and thiazolidinediones was mediated by changes in LPL and apo C-lll concentrations.
LPL mRNA and activity levels and apo C-lll production can be regulated in a tissue-specific fashion by PPARa activators and PPARy ligands. The modulation of LPL and apo C-lll gene expression by these compounds is mediated by specific response elements or PPREs in their promoters.
In adipose tissue, the increase in LPL production after treatment with thiazolidinediones will enhance the clearance of plasma triglycerides and provide the (pre)adipocytes with additional fatty acids, which can further stimulate the transactivation capacity of PPAR or which can be stored under form of triglycerides.
In the liver, the enhanced production of LPL together with the reduced production of apo C-lll, contributes to the hypolipidemic action of these compounds.
This tissue-selective induction of gene transcription by activators of different PPARs, demonstrates the feasibility of the development of highly specific PPAR subtype-specific agonists and antagonists, which can be used as drugs.
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